journal logo

Welcome to Cancer Gene Therapy

The essential gene and cellular therapy resource for cancer researchers and clinicians.

Announcements

  • LATEST COLLECTION: While patients with metastatic UM continue to represent a population in need of better outcomes, meaningful progress has been made in deepening our understanding of the disease biology and development of novel therapeutics. We hope this collection proves a valuable resource for those in the scientific and medical communities committed to improving UM patient outcomes.

  • Each month or so we will be featuring one of our editorial team, allowing them an opportunity to impart some of their wisdom and knowledge with you, our authors and readers, and you the opportunity to get to know them a little better. Currently featuring Associate Editor, Leandro Castellano

  • New QC checks introduced in CGT

    As part of CGT’s continuous effort to provide high quality & innovative research, we have introduced new QC checks: Requirement of a cover letter in an institutional letterhead at first submission; Requirement for institutional e-mail(s) addresses for the corresponding author(s); Inclusion of an Author Contribution statement in the submitted manuscript; Availability of original data upon request

Cancer Gene Therapy is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

Advertisement

collection image

Reader's Choice: the best of Cancer Gene Therapy 2022

In this collection we highlight a selection of articles from 2022, which top the list of the journal’s most cited, downloaded and most shared (including press coverage, blogs, Twitter, Facebook and Weibo). The articles showcase the breadth of scope and coverage that the journal consistently delivers to its readers.
Collection

Advertisement